1393891-19-4

Basic information

• Product Name: (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid
• Synonyms: (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid
• CAS NO: 1393891-19-4
• Molecular Weight: 582.495
• Mol File: 1393891-19-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid(1393891-19-4)
• EPA Substance Registry System: (S,Z)-2-(5-(4-(2-(2-bromophenyl)-2-oxoethoxy)benzylidene)-4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid(1393891-19-4)

Safety Data

• Hazardous Substances Data: 1393891-19-4(Hazardous Substances Data)

Upstream product

• 161192-25-2 (S)-2-(4-oxo-2-thioxothiazolidin-3-yl)-3-phenylpropanoic acid 
• 1393890-86-2 C₁₅H₁₁BrO₃ 
• 2142-69-0 2-bromophenyl methyl ketone 
• 49851-55-0 2,2'-dibromoacetophenone 

Relevant articles and documents

Synthesis and bioactivity evaluation of rhodanine derivatives as potential anti-bacterial agents

Five series of (Z)-5-(4-(2-oxo-2-phenylethoxy)benzylidene)-2- thioxothiazolidin-4-one derivatives (I-V) were synthesized, characterized, and evaluated for their anti-bacterial activity. Most of the synthesized compounds showed potent inhibition against several Gram-positive bacteria (including multidrug-resistant clinical isolates) with MIC values in the range of 1-32 μg/mL. Compounds IIIi, Vb and Vc presented the most potent activity, showing four-fold more potency than norfloxacin (MIC = 8 μg/mL and 4 μg/mL) and 64-fold more activity than oxacillin (MIC > 64 μg/mL) against MRSA CCARM 3167 and 3506 strains with MIC values of 1 μg/mL, and 64-fold more potency than norfloxacin (MIC > 64 μg/mL) and comparable activity to oxacillin (MIC = 1 μg/mL) against the QRSA CCARM 3505 and 3519 strains. None of the compounds exhibited any activity against the Gram-negative bacteria Escherichia coli 1356 at 64 μg/mL.